AR106913A1 - Tratamiento de degeneración de la retina mediante el uso de células progenitoras - Google Patents
Tratamiento de degeneración de la retina mediante el uso de células progenitorasInfo
- Publication number
- AR106913A1 AR106913A1 ARP160103730A ARP160103730A AR106913A1 AR 106913 A1 AR106913 A1 AR 106913A1 AR P160103730 A ARP160103730 A AR P160103730A AR P160103730 A ARP160103730 A AR P160103730A AR 106913 A1 AR106913 A1 AR 106913A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- population
- derived cells
- postpartum derived
- blood
- Prior art date
Links
- 201000007737 Retinal degeneration Diseases 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 7
- 108010045374 CD36 Antigens Proteins 0.000 abstract 2
- 108060008245 Thrombospondin Proteins 0.000 abstract 2
- 102000002938 Thrombospondin Human genes 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 230000000242 pagocytic effect Effects 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 102100022464 5'-nucleotidase Human genes 0.000 abstract 1
- 102100022749 Aminopeptidase N Human genes 0.000 abstract 1
- 101100208237 Bos taurus THBS2 gene Proteins 0.000 abstract 1
- 102100032912 CD44 antigen Human genes 0.000 abstract 1
- 101150022345 GAS6 gene Proteins 0.000 abstract 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 abstract 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 abstract 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 abstract 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 abstract 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 abstract 1
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 abstract 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 abstract 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 abstract 1
- 102000004890 Interleukin-8 Human genes 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 101710191666 Lactadherin Proteins 0.000 abstract 1
- 102100039648 Lactadherin Human genes 0.000 abstract 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 abstract 1
- 102000003729 Neprilysin Human genes 0.000 abstract 1
- 108090000028 Neprilysin Proteins 0.000 abstract 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 abstract 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 1
- 102100022647 Reticulon-1 Human genes 0.000 abstract 1
- 101710122684 Reticulon-1 Proteins 0.000 abstract 1
- 102100026966 Thrombomodulin Human genes 0.000 abstract 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 210000004700 fetal blood Anatomy 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 abstract 1
- 229940096397 interleukin-8 Drugs 0.000 abstract 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 210000000608 photoreceptor cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 210000003954 umbilical cord Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
Reivindicación 1: El uso de una composición que comprende una población de células derivadas del posparto en el tratamiento de una afección ocular degenerativa o la reducción de la pérdida de células fotorreceptoras en la degeneración de la retina, en donde las células derivadas del posparto se aíslan del tejido del cordón umbilical humano sustancialmente libre de sangre, y en donde la población de células derivadas del posparto modula los receptores fagocíticos integrina avb5 y CD36. Reivindicación 2: El uso de acuerdo con la reivindicación 1, en donde las células derivadas del posparto secretan moléculas puente seleccionadas a partir de MFG-E8, Gas6, trombospondina (TSP)-1 y TSP-2, y en donde las moléculas puente se unen a los receptores fagocíticos integrina avb5 y CD36. Reivindicación 3: El uso de acuerdo con la reivindicación 1, en donde la población de células aisladas del tejido del cordón umbilical humano sustancialmente libre de sangre tiene la capacidad de expandirse en cultivo, tiene el potencial de diferenciarse en células de al menos un fenotipo neural, conserva un cariotipo normal después de los pases y tiene las siguientes características: a) potencial para 40 duplicaciones de la población en cultivo; b) producción de CD10, CD13, CD44, CD73 y CD90; c) falta de producción de CD31, CD34, CD45, CD117, y CD141, y d) mayor expresión de genes que codifican interleucina 8 y reticulón 1 con respecto a una célula humana que es un fibroblasto, una célula madre mesenquimal o una célula de médula ósea de la cresta ilíaca.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263463P | 2015-12-04 | 2015-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106913A1 true AR106913A1 (es) | 2018-02-28 |
Family
ID=58797699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103730A AR106913A1 (es) | 2015-12-04 | 2016-12-05 | Tratamiento de degeneración de la retina mediante el uso de células progenitoras |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20170157179A1 (es) |
| EP (1) | EP3384009A4 (es) |
| JP (1) | JP2019501888A (es) |
| KR (1) | KR20180088713A (es) |
| CN (1) | CN108291199A (es) |
| AR (1) | AR106913A1 (es) |
| AU (1) | AU2016365312A1 (es) |
| BR (1) | BR112018011278A2 (es) |
| CA (1) | CA3007198A1 (es) |
| MX (1) | MX2018006729A (es) |
| PH (1) | PH12018501045A1 (es) |
| RU (1) | RU2018122461A (es) |
| SG (1) | SG11201803781XA (es) |
| TW (1) | TW201729819A (es) |
| WO (1) | WO2017095991A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
| KR102224115B1 (ko) | 2020-01-10 | 2021-03-09 | 경북대학교병원 | 3차원 바이오프린팅 기술을 이용한 망막 세포 배양용 구조체 및 이의 활용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001855A (en) * | 1998-01-02 | 1999-12-14 | Hoffman-La Roche Inc. | Thiazole derivatives |
| US20010041670A1 (en) * | 1999-12-06 | 2001-11-15 | Ronit Simantov | Thrombospondin-binding region of histidine-rich glycoprotein and method of use |
| AU2002319282B2 (en) * | 2001-08-01 | 2007-06-28 | Merck Patent Gmbh | Integrin inhibitors for the treatment of eye diseases |
| US8790637B2 (en) * | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
| WO2005001080A2 (en) * | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
| CA2705541C (en) * | 2007-11-15 | 2018-09-11 | The Feinstein Institute For Medical Research | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8 |
| KR102165421B1 (ko) * | 2011-05-09 | 2020-10-14 | 알레그로 파마슈티칼스, 인코포레이티드. | 인테그린 수용체 길항물질 및 이의 사용 방법 |
| WO2013184976A2 (en) * | 2012-06-06 | 2013-12-12 | Northwestern University | Compositions and methods for antigen-specific tolerance |
| SG11201704668PA (en) * | 2014-12-16 | 2017-07-28 | Janssen Biotech Inc | Treatment of retinal degeneration using progenitor cells |
-
2016
- 2016-12-01 WO PCT/US2016/064336 patent/WO2017095991A1/en not_active Ceased
- 2016-12-01 MX MX2018006729A patent/MX2018006729A/es unknown
- 2016-12-01 SG SG11201803781XA patent/SG11201803781XA/en unknown
- 2016-12-01 US US15/366,599 patent/US20170157179A1/en not_active Abandoned
- 2016-12-01 EP EP16871469.9A patent/EP3384009A4/en not_active Withdrawn
- 2016-12-01 CA CA3007198A patent/CA3007198A1/en not_active Abandoned
- 2016-12-01 JP JP2018528794A patent/JP2019501888A/ja active Pending
- 2016-12-01 AU AU2016365312A patent/AU2016365312A1/en not_active Abandoned
- 2016-12-01 RU RU2018122461A patent/RU2018122461A/ru not_active Application Discontinuation
- 2016-12-01 CN CN201680071080.7A patent/CN108291199A/zh active Pending
- 2016-12-01 BR BR112018011278A patent/BR112018011278A2/pt not_active Application Discontinuation
- 2016-12-01 KR KR1020187018529A patent/KR20180088713A/ko not_active Withdrawn
- 2016-12-02 TW TW105139990A patent/TW201729819A/zh unknown
- 2016-12-05 AR ARP160103730A patent/AR106913A1/es unknown
-
2018
- 2018-05-16 PH PH12018501045A patent/PH12018501045A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108291199A (zh) | 2018-07-17 |
| BR112018011278A2 (pt) | 2018-11-21 |
| TW201729819A (zh) | 2017-09-01 |
| WO2017095991A1 (en) | 2017-06-08 |
| JP2019501888A (ja) | 2019-01-24 |
| CA3007198A1 (en) | 2017-06-08 |
| KR20180088713A (ko) | 2018-08-06 |
| US20170157179A1 (en) | 2017-06-08 |
| AU2016365312A1 (en) | 2018-05-24 |
| MX2018006729A (es) | 2018-11-09 |
| SG11201803781XA (en) | 2018-06-28 |
| RU2018122461A (ru) | 2020-01-13 |
| EP3384009A4 (en) | 2019-06-12 |
| EP3384009A1 (en) | 2018-10-10 |
| PH12018501045A1 (en) | 2019-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025010485A (es) | Composiciones de vcar y metodos de uso | |
| CO2021006362A2 (es) | Construcciones de ácido nucleico y métodos de uso | |
| PE20170188A1 (es) | Formulaciones y metodos de tratamiento con queratina | |
| MX2018000897A (es) | Celulas madre hematopoyeticas que expresan pd-l1 y usos. | |
| NZ797963A (en) | Antibodies against pd-l1 | |
| BR112021019411A2 (pt) | Métodos para a produção de células car-nk e uso das mesmas | |
| MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
| BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
| MX2019008872A (es) | Prevencion y tratamiento de da?o o enfermedad osea y cartilago. | |
| MX2017002459A (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
| MX2018001531A (es) | Medio de cultivo celular complementado con taurina y metodos de uso. | |
| MX2019012311A (es) | Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso. | |
| DOP2016000042A (es) | Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos | |
| MX2017007138A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| CO2017000510A2 (es) | Constructos de car | |
| WO2011130624A3 (en) | Sustained polypeptide expression from synthetic, modified rnas and uses thereof | |
| RU2017124983A (ru) | Лечение дегенерации сетчатки с использованием клеток-предшественников | |
| CL2017001301A1 (es) | Composiciones oftálmicas estabilizadas de omega 3 | |
| BR112021019349A2 (pt) | Células-tronco preparadas altamente funcionais | |
| MX377300B (es) | Terapia con células madre en patologías endometriales. | |
| MX2019013485A (es) | Composiciones para el cuidado bucal y metodos de uso. | |
| CL2017002357A1 (es) | Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos | |
| AR112356A1 (es) | Métodos para obtener células de tejido arterial del cordón umbilical humano postparto | |
| CL2018001104A1 (es) | Composición para el cuidado de la piel y procedimiento asociado. | |
| AR112418A1 (es) | Método para modular células de müller |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |